Shopping Cart
- Remove All
 
Your shopping cart is currently empty
Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticaria (CU) treatment.

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 1 mg | $98 | In Stock | |
| 5 mg | $233 | In Stock | |
| 10 mg | $378 | In Stock | |
| 25 mg | $635 | In Stock | |
| 50 mg | $793 | In Stock | |
| 100 mg | $1,220 | In Stock | |
| 200 mg | $1,650 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $261 | In Stock | 
| Description | Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticaria (CU) treatment.  | 
| Targets&IC50 |  IL-8 (Cell-free assay):2.5 nM, BTK (Cell-free assay):1.3 nM, CD69 (Cell-free assay):18 nM, Btk enzymatic (B cell):0.023 μM, BTK:1 nM  | 
| In vitro | Remibrutinib inhibits Btk enzymatic activity (IC50: 1 nM in a biochemical enzyme assay). Remibrutinib inhibits Btk enzymatic activity in the blood (IC50: 0.023 μM in vitro B cell activation assay), the whole blood is collected from the abdominal aorta of anesthetized adult male Lewis rats[1].  | 
| Molecular Weight | 507.53 | 
| Formula | C27H27F2N5O3 | 
| Cas No. | 1787294-07-8 | 
| Smiles | CN(CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C)C(=O)C=C | 
| Relative Density. | 1.332 g/cm3 (Predicted) | 
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 240 mg/mL (472.88 mM), Sonication is recommended.   | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.85 mM), Sonication is recommended.  Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table  | ||||||||||||||||||||||||||||||||||||
DMSO 
  | ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.